PDCD1 and non-Hodgkin lymphoma: While the low response rates in other lymphoma subtypes have been underwhelming, further clinical trials are warranted to determine whether other subtypes of NHL responses to PD-1 blockade can be improved through the combination with immunogenic anti-CD-20 monoclonal antibodies or dual checkpoint inhibition.